

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE-

L



Application No.:

Scott Siegel 10/044,534

Group Art Unit:

Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and

1644

RECEIVED

Filed:

January 10, 2002

Examiner:

Not Assigned

OCT 1 8 2002

Confirmation No.:

4929

TECH CENTER 1600/2900

Title:

[ ]

under 37 CFR 1.97(i):

(Filed after payment of issue fee)

METHODS OF TREATING ANKYLOSIS WITH CHIMERIC ANTI-TNF

**ANTIBODIES** 

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202 on Date Signature			
Linda M. Amato			
Typed or printed name of person signing certificate			

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

P.O. I	tant Commissioner for Patents Box 2327
Arlıng	gton, VA 22202 20231
Sir: This I	nformation Disclosure Statement is submitted:
[ ]	under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[ ]	under 37 CFR 1.97(c) together with either:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[ ]	under 37 CFR 1.97(d) together with:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, and
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

### Statement Under 37 CFR 1.97(e) Each item of information contained in this Information Disclosure Statement was first cited in [ ] any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or No item of information contained in this Information Disclosure Statement was cited in a [ ]communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR } 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Statement Under 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000 Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. [X]Enclosed herewith is form PTO-1449: [ ] Copies of the cited references are enclosed. [X]Copies of cited references are enclosed except those entered in prior applications, U.S. Application No. 09/927,703, to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references. The listed references were cited in the enclosed International Search Report in a [ ] counterpart foreign application. [X]The "concise explanation" requirement (non-English references) for references AN7 and AO7 under 37 CFR 1.98(a)(3) is satisfied by: the explanation provided on the attached sheet. the explanation provided in the Specification. [ ] submission of the enclosed International Search Report. the enclosed English language abstracts and also reference AH2, which is a U.S. [X]equivalent of AN7. Copies of references AH2, AN7 and AO7 are enclosed in prior application U.S. Application No. 09/927,703 to which priority under 35 U.S.C. 120 is claimed. Applicant requests that the following pending applications be considered: [X] U.S. Patent Application No. 10/227,488, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed August 23, 2002, Docket No.: 0975.1005-025

Examiner Date

- [X] The specification for the above cited co-pending application is identical to the present specification (10/044,534). Therefore, only a copy of the current claims for this application is enclosed. Copies of the specifications of the co-pending application will be provided upon request.
- A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

#### Method of payment:

- [ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted.

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deliste E. Sanders

Registration No.: 42,122 Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated:

October 9,2002

PTC-1449	REPRODUCED
_	

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

October 9, 2002

se several sheets if necessary)

ATTORNEY DOCKET NO. 0975.1005-016

APPLICATION NO. 10/044,534

APPLICANT

Junming Le et al.

FILING DATE January 10, 2002

GROUP 1644

U.S.	PATENT	DOCUMENTS
------	--------	-----------

EXAM-							
INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
•	AE2				<b> </b>		
	AEZ	4,816,567	03/28/89	Cabilly et al.		KE(	EIVED
[]	AF2	5,075,236	30/04/05		<del></del>		
<b></b>		3,073,236	12/24/91	Yone et al.		OCT	18 2002
1	AG2	5,959,087	09/28/99	Dathia			
		27337,007	09/20/99	Rathjen et al.	TA	CH CENT	ED 1000/0000
11	AH2	5,360,716	11/01/94	Ohmoto, Y. et al.		TO THE	ER 1600/2900
<del>                                     </del>			, 51, 51	ommoco, r. et al.			
							Į.

#### FOREIGN PATENT DOCUMENTS

11				1				
<b> </b>		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL YES	ATION NO
	AM7	WO92/01059	23 JAN 92	PCT				
	AN7	02-227095	10 SEP 90	JP			Х	
	A07	61-047500	07 MAR 86	JP			Х	
				·				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AT11	Yan, L. et al., "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha", Chinese J. Biotechnology, 7(2):121-126 (1991).

Mateo, C. et al., "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", Hybridoma, 19(6):463-471 (2000).

Paul, W.E. (Ed.), Fundamental Immunology, 3<sup>rd</sup> Edition, Pub. Raven Press Ltd., pp. 292-293 (1993).

Borrebaeck, C.A.K. (Ed.), Antibody Engineering, 2<sup>nd</sup> Edition, Pub. Oxford University Press, p. 291 (1995).

Socher, S. et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor", Proc. Natl. Acad. Sci., USA 84:8829-8833 (1987).

Goh, C., "Tumour Necrosis Factors in Clinical Practice", Annals of the Academy of Medicine, 19(2):235-239 (1990).

EXAMINER

AX11

DATE CONSIDERED